Shares of Daxor Corporation (NASDAQ:DXR – Get Free Report) traded down 0.9% during trading on Thursday . The company traded as low as $10.48 and last traded at $10.39. Approximately 314 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 1,593 shares. The stock had previously closed at $10.48.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Daxor in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.
View Our Latest Analysis on Daxor
Daxor Stock Performance
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of DXR. Aristides Capital LLC bought a new position in shares of Daxor in the first quarter worth approximately $403,000. Crescent Grove Advisors LLC purchased a new stake in Daxor in the first quarter valued at approximately $104,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in Daxor during the first quarter valued at approximately $245,000. Nano Cap New Millennium Growth Fund L P bought a new stake in Daxor during the fourth quarter valued at approximately $184,000. Finally, Osaic Holdings Inc. purchased a new position in Daxor in the 2nd quarter worth approximately $86,000. Hedge funds and other institutional investors own 1.34% of the company’s stock.
About Daxor
Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.
In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.
Featured Articles
- Five stocks we like better than Daxor
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.
